Simultaneous or Delayed Administration of Hepatocyte Growth Factor Equally Represses the Fibrotic Changes in Murine Lung Injury Induced by Bleomycin

Masahiro Yaekashiwa(Tohoku University), Toshihiro Nukiwa(Tohoku University), Shoichi Nakayama(Tohoku University), Tohru Takahashi(Tohoku University), Kunio Matsumoto(Kanazawa University), Tatsuya Abé(Tohoku University), Toshihiko Sakai(Tohoku University), Ken Satoh(Tohoku University), Toshikazu Nakamura(The University of Osaka), Kazuya OHNUMA(Tohoku University)
American Journal of Respiratory and Critical Care Medicine
December 1, 1997
10.1164/ajrccm.156.6.9611057
Cited by 203

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
|Journal of Clinical Oncology|2009|516